

RESEARCH

Open Access



Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by disrupting HDAC2/Sin3A/MeCP2 corepressor complex

Hung-Sheng Hua¹, Heng-Ching Wen¹, Hong-Sheng Lee^{1,4}, Chih-Ming Weng^{2,4}, Fara Silvia Yuliani⁶, Han-Pin Kuo^{3,4,5}, Bing-Chang Chen^{2,4*} and Chien-Huang Lin^{1,4*} 

Abstract

Background Reduction of histone deacetylase (HDAC) 2 expression and activity may contribute to amplified inflammation in patients with severe asthma. Connective tissue growth factor (CTGF) is a key mediator of airway fibrosis in severe asthma. However, the role of the HDAC2/Sin3A/methyl-CpG-binding protein (MeCP) 2 corepressor complex in the regulation of CTGF expression in lung fibroblasts remains unclear.

Methods The role of the HDAC2/Sin3A/MeCP2 corepressor complex in endothelin (ET)-1-stimulated CTGF production in human lung fibroblasts (WI-38) was investigated. We also evaluated the expression of HDAC2, Sin3A and MeCP2 in the lung of ovalbumin-induced airway fibrosis model.

Results HDAC2 suppressed ET-1-induced CTGF expression in WI-38 cells. ET-1 treatment reduced HDAC2 activity and increased H3 acetylation in a time-dependent manner. Furthermore, overexpression of HDAC2 inhibited ET-1-induced H3 acetylation. Inhibition of c-Jun N-terminal kinase, extracellular signal-regulated kinase, or p38 attenuated ET-1-induced H3 acetylation by suppressing HDAC2 phosphorylation and reducing HDAC2 activity. Overexpression of both Sin3A and MeCP2 attenuated ET-1-induced CTGF expression and H3 acetylation. ET-1 induced the disruption of the HDAC2/Sin3A/MeCP2 corepressor complex and then prompted the dissociation of HDAC2, Sin3A, and MeCP2 from the CTGF promoter region. Overexpression of HDAC2, Sin3A, or MeCP2 attenuated ET-1-stimulated AP-1-luciferase activity. Moreover, Sin3A- or MeCP2-suppressed ET-1-induced H3 acetylation and AP-1-luciferase activity were reversed by transfection of HDAC2 siRNA. In an ovalbumin-induced airway fibrosis model, the protein levels of HDAC2 and Sin3A were lower than in the control group; however, no significant difference in MeCP2 expression was observed. The ratio of phospho-HDAC2/HDAC2 and H3 acetylation in the lung tissue were higher in this model than in the control group. Overall, without stimulation, the HDAC2/Sin3A/MeCP2 corepressor complex inhibits CTGF expression by regulating H3 deacetylation in the CTGF promoter region in human lung fibroblasts. With ET-1 stimulation, the HDAC2/Sin3A/MeCP2 corepressor complex is disrupted and dissociated from the CTGF promoter region; this is followed by AP-1 activation and the eventual initiation of CTGF production.

*Correspondence:

Bing-Chang Chen
bcchen@tmu.edu.tw
Chien-Huang Lin
chlin@tmu.edu.tw

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions The HDAC2/Sin3A/MeCP2 corepressor complex is an endogenous inhibitor of CTGF in lung fibroblasts. Additionally, HDAC2 and Sin3A may be of greater importance than MeCP2 in the pathogenesis of airway fibrosis.

Keywords HDAC2, Sin3A, MeCP2, ET-1, CTGF, Airway fibrosis, Lung fibroblasts

Background

Lung fibrosis is a heterogeneous respiratory disease with a high mortality rate. It is characterized by scar formation in lung tissue, which causes lung architecture destruction, leading to death [54]. Subepithelial fibrosis is characterized by extensive deposition of extracellular matrix (ECM), including collagens, in the airway wall, which may lead to progressive airflow obstruction [6, 50]. The pathogenesis of lung fibrosis primarily involves fibroblast differentiation and proliferation [55]. In pathological fibrosis, fibroblasts differentiate into myofibroblasts, which excessively synthesize ECM [15]. Fibroblast differentiation is regulated by various profibrotic factors, such as connective tissue growth factor (CTGF) [56], transforming growth factor (TGF)- β 1 [40], and thrombin [5].

CTGF, formerly known as CCN2, mediates various biological processes, such as ECM production and tissue modeling, as well as cell adhesion, migration, proliferation, and differentiation [34]. A study indicated that CTGF is an essential downstream mediator for TGF- β 1-induced ECM production and myofibroblast differentiation in Graves' orbital fibroblast [48]. In bleomycin-induced lung fibrosis, CTGF contributes to lung fibrosis by promoting type I collagen production in lung fibroblasts [43]. CTGF plays a central mediating role in tissue fibrosis [38]. In our previous studies, we have demonstrated that CTGF production in human lung fibroblasts is stimulated by several profibrotic factors, such as CXC motif chemokine ligand 12, thrombin, hypoxia, and endothelin (ET)-1 [9, 11, 37, 53].

Elevated expression of ET-1 by the bronchial epithelium is associated with airflow obstruction and airway remodeling, and it is often observed in severe refractory asthma [42]. In our previous studies, we have observed the following: first, the ET_A receptor (ET_AR)-dependent pathway mediates CTGF expression, which prompts fibrocyte differentiation into myofibroblasts in chronic obstructive asthma [52]; second, ET-1 stimulates CTGF production through c-Jun N-terminal kinase (JNK)/activator protein (AP)-1 activation in lung fibroblasts [53]; third, ET-1 activates HDAC7 and p300, thereby leading to the initiation of AP-1 transcriptional activity and eventually the promotion of CTGF production in lung fibroblasts [22].

Epigenetic modifications of histone play a pivotal role in both the regulation of gene expression and the development of various diseases [8]. Histone acetylation

and deacetylation are involved in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD) through the regulation of inflammatory genes [3]. Histone acetylation and deacetylation are controlled by histone acetyltransferases and histone deacetylase (HDAC). Several studies have suggested that a reduction in HDAC2 expression and activity may contribute to amplified inflammation in individuals with severe asthma or COPD [13, 24]. In steroid-resistant asthma, glucocorticoid receptor β contributes to steroid resistance by inhibiting HDAC2 expression [35]. HDAC2 reduction plays a crucial role in glucocorticoid insensitivity by repressing NF- κ B-mediated gene expression [25]. Passive smoking impairs HDAC2 function, which may contribute to corticosteroid-insensitive inflammation in children with severe asthma [32].

HDAC2 is known to form a corepressor complex with a large scaffold protein, Sin3A, to regulate gene transcription [46]. The Sin3A/HDAC2 complex serves as a negative regulator of the inflammatory gene program in lipopolysaccharide-activated human macrophages [26]. A study indicated that methyl-CpG-binding protein 2 (MeCP2) recruits HDAC2 and Sin3A to promote the deacetylation of histone tails, which results in gene silencing [28]. The methylation of DNA results in the recruitment of HDAC-containing complexes through MeCP2 to strengthen histone deacetylation, which then leads to reinforced epigenetic silencing of the COX2 gene in fibroblasts from patients with idiopathic pulmonary fibrosis [14]. However, the role of the HDAC2/Sin3A/MeCP2 corepressor complex in ET-1-stimulated CTGF expression remains unclear.

In this study, we evaluated the roles of HDAC2, Sin3A, and MeCP2 in ET-1-stimulated CTGF expression in lung fibroblasts. We observed that the HDAC2/Sin3A/MeCP2 corepressor complex is an endogenous inhibitor of CTGF expression. ET-1 caused the disruption of the HDAC2/Sin3A/MeCP2 corepressor complex, thereby reducing HDAC2 activity and increasing histone H3 acetylation; this was followed by AP-1 recruitment to the CTGF promoter, which in turn promoted CTGF expression. Moreover, we observed a reduction in HDAC2 and Sin3A, but not MeCP2, in the lung of the ovalbumin (OVA)-induced airway fibrosis model, indicating that HDAC2 and Sin3A might play a greater role than MeCP2 in the pathogenesis of airway fibrosis.

Materials and methods

Materials

WI-38 normal human embryonic lung fibroblast cell lines (ATCC CCL-75) were purchased from American Type Culture Collection (Manassas, VA, USA). Recombinant human ET-1 was obtained from Bachem Americas (Torrance, CA, USA). Minimum essential medium (MEM), Lipofectamine 3000 reagent, and fetal bovine serum (FBS) were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). The chromatin immunoprecipitation (ChIP) assay kit was obtained from Upstate Biotechnology (Lake Placid, NY, USA). 2X Tools Tag PCR MasterMix with loading dye was obtained from BIOTOOLS (BIOTOOLS, Taipei, Taiwan). All materials for Western blots were acquired from Bio-Rad (Hercules, CA, USA). Antibodies specific for HDAC2, CTGF, anti-mouse, and anti-rabbit immunoglobulin G (IgG)-conjugated horseradish peroxidase were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies specific for Sin3A, MeCP2, and GFP-tag, were purchased from Cell Signaling Technology (Danvers, MA, USA), and the anti- α -tubulin antibody was purchased from Transduction Laboratories (Lexington, KY, USA). Antibodies specific for H3, acetyl-H3, phospho-HDAC2 (S394), HDAC7, and HA-tag were obtained from Abcam (Cambridge, MA, USA). Anti-rabbit IgG (Alexa Fluor[®] 555) was obtained from Abcam. Alexa Fluor[®] 488-conjugated HDAC2 antibody and Alexa Fluor[®] 647-conjugated phospho-HDAC2 (S394) antibody were purchased from Bioss (Woburn, MA, USA). HDAC2 activity assay kit were purchased from Abcam. HDAC2-HA, Sin3A-HA, MeCP2-HA, and HDAC7-GFP plasmid were purchased from GeneCopoeia (Rockville, MD, USA). pBK-CMV-Lac Z (*LacZ*) was obtained from Dr. W-W. Lin (National Taiwan University, Taipei, Taiwan). pAP-1-Luc *cis*-Reporter plasmid was obtained from Stratagene (Santa Clara, CA, USA). The luciferase assay system was procured from Promega (Madison, WI, USA), OVA was bought from MilliporeSigma (Burlington, MA, USA), aluminum hydroxide was obtained from Thermo Fisher Scientific (Waltham, MA, USA), and all other chemicals were acquired from MilliporeSigma.

Cell culture

WI-38 cells at passages 22–30 were used to conduct experiments. Cells were grown in a CO₂ incubator at 37 °C. MEM supplemented with 10% FBS was used for cell cultures. For transfection and immunoblotting, cells were seeded into 6-cm dishes. For Co-IP and ChIP assays, cells were transferred into 10-cm dishes. For transfection and luciferase assays, cells were seeded into 12-well plates.

Transfection and luciferase reporter assays

WI-38 cells were seeded into 12-well plates (5×10^4 cells/well). Plasmids of AP-1-Luc, *Lac Z*, HDAC2-HA, Sin3A-HA, MeCP2-HA, or HDAC2 siRNA were transfected into WI-38 cells by using Lipofectamine 3000. After transfection for 6 h, the culture medium was replaced with serum-free medium, and the cells were incubated overnight. The WI-38 cells were then treated with ET-1 for 16 h; subsequently, their luciferase activity was assayed. The level of *LacZ* was used to normalize luciferase activity.

Western blot analysis

Cell lysates were separated through sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. The membrane was immersed in bovine serum albumin solution (1%) for 1 h at room temperature to block nonspecific antigens on the membrane and was subsequently incubated with primary antibodies at 4 °C overnight. Antibodies specific for HDAC2, CTGF, phospho-HDAC2 (S394), Sin3A, MeCP2, acetyl-H3, H3, HDAC7, GFP-tag, HA-tag, or α -tubulin were used to target the proteins. After incubation with primary antibodies, the membrane was incubated with secondary antibody for 1 h. The blots were displayed using enhanced chemiluminescence reagents. Quantitative data were obtained using a scientific imaging system (Kodak, Rochester, NY, USA).

Coimmunoprecipitation

Cell lysates were collected and centrifuged. The supernatants were incubated with protein A/G beads and antibodies specific for HDAC2, Sin3A, or MeCP2 at 4 °C overnight for coimmunoprecipitation. The interaction between proteins was then assayed using Western blotting.

ChIP assay

The samples were sonicated, centrifuged at $15,000 \times g$ at 4 °C for 10 min, and subsequently immunoprecipitated with HDAC2, Sin3A, MeCP2, acetyl-H3, or rabbit IgG antibody and protein A/G beads overnight. After immunoprecipitation, DNA was purified to amplify the AP-1 binding site by using polymerase chain reaction (PCR). The primer sequences were as follows: 5'-CGT CCC TTG TCC TTG CCT AT-3' (sense) and 5'-GCT CGA CCT CAC ACG GTC GA-3' (antisense). The PCR involved 45 cycles of amplification at 95 °C for 30 s, 52 °C for 60 s, and 72 °C for 30 s.

Sensitization and antigen challenge of an asthmatic animal model

Female C57BL/6 mice (BioLASCO, Taipei, Taiwan) aged 7 weeks were used in the experiments. They were divided into two groups ($n=10$ per group): control (phosphate-buffered saline [PBS]) and OVA treatment. The mice were immunized through subcutaneous injections of 50 μg of OVA adsorbed on 4 mg of aluminum hydroxide in 200 μL of PBS on days 1, 8, and 15. OVA challenges (20 $\mu\text{g}/50 \mu\text{L}$ in PBS) were initiated on day 28 and were repeated twice a week for 8 weeks in an ultrasonic nebulizer chamber. The control mice were treated similarly with PBS but without OVA. The mice were sacrificed at 12 weeks. All animal experimental protocols were approved by the Taipei Medical University Institutional Animal Care and Use Committee (LAC-101-0243).

Immunofluorescence (IF) staining

The expression of phospho-HDAC2, HDAC2, and Sin3A in the lung of OVA-treated mice and in ET-1-stimulated WI-38 cells were visualized by immunofluorescent staining. The paraffin-embedded lung tissue sections of mice were processed for antigen retrieval. WI-38 cells were stimulated with ET-1 for 10 min and then fixed with 4% formaldehyde for 10 min at 37 °C. The lung tissue sections or WI-38 cells were blocked with 5 mg/mL bovine serum albumin for 1 h. Alexa Fluor[®] 488-conjugated HDAC2 antibody and Alexa Fluor[®] 647-conjugated phospho-HDAC2 (S394) antibody were stained respectively for 2 h. Sin3A antibody was stained for 2 h and incubated with Alexa Fluor[®] 555-conjugated secondary antibody for another 1 h. Each slide was stained with DAPI to visualize nuclei and as a live cell marker. The immunofluorescence staining slides were examined through a fluorescence microscope.

Statistical analysis

At least three independent experiments were conducted. Data are presented as mean \pm standard error of the mean. A one-way analysis of variance was conducted followed by Dunnett's test. In all cases, $p < 0.05$ was considered statistically significant. The calculation process of inhibition rate is as follows: the percentage of control = A; the percentage of ET-1 stimulation group = B; the percentage of inhibitors with ET-1 stimulation = C; inhibition rate = $1 - [(C - A)/(B - A)]$.

Results

HDAC2 suppressed ET-1-induced CTGF production

Reduced HDAC2 activity is associated with the elevation of inflammatory gene expression in patients with severe asthma [2]. In this study, we evaluated the role of HDAC2 in ET-1-stimulated CTGF expression in WI-38

cells. HDAC2 overexpression (0.5 and 1 μg) attenuated ET-1-stimulated CTGF production in a dose-dependent manner ($n=4$; Fig. 1A). Without ET-1 stimulation, transfection of HDAC2 small interfering RNA (siRNA; 100 nM) increased CTGF protein level in WI-38 cells by $226\% \pm 25\%$ ($n=5$; Fig. 1B). With ET-1 stimulation, transfection of HDAC2 siRNA enhanced the CTGF protein level by $157\% \pm 20\%$ ($n=5$; Fig. 1B). Thus, without stimulation, HDAC2 was an endogenous inhibitor of CTGF expression. With ET-1 stimulation, HDAC2 negatively regulated ET-1-stimulated CTGF production in WI-38 cells.

ET-1 induced histone H3 acetylation through a reduction in HDAC2 activity

CTGF expression is regulated through the epigenetic modification of DNA, such as histone acetylation [12]. In our previous study, HDAC7 regulated ET-1-induced CTGF expression through the activation of AP-1 in WI-38 cells [22]. In this study, we evaluated the role of HDAC2 and HDAC7 in ET-1-induced histone H3 acetylation. When cells were treated with ET-1 for 5–30 min, the HDAC2 activity decreased in a time-dependent manner ($n=3$; Fig. 2A). By contrast, treating the cells with ET-1 for 5–60 min increased H3 acetylation in a time-dependent manner ($n=4$; Fig. 2B). Further, HDAC2 overexpression attenuated ET-1-stimulated H3 acetylation in a dose-dependent manner ($n=4$; Fig. 2C). However, overexpression of HDAC7 did not affect ET-1-induced H3 acetylation ($n=5$; Fig. 2D). Thus, ET-1 induced H3 acetylation by suppressing HDAC2 activity, but not HDAC7 activation.

JNK, extracellular signal-regulated kinase, and p38 were involved in ET-1-induced H3 acetylation through the regulation of HDAC2 phosphorylation and HDAC2 activity

HDAC2 phosphorylation at serine sites S394, S422, and S424 negatively regulates its deacetylase activity [1]. Moreover, the phosphorylation of HDAC2 is crucial for the dissociation of HDAC2 and Sin3A [30]. In this study, we found that incubation of cells with ET-1 for 1–10 min stimulated HDAC2 phosphorylation at S394 in a time-dependent manner ($n=3$; Fig. 3A). In addition, we identify the changes and location of phospho-HDAC2, HDAC2, and Sin3A in WI-38 cells by IF staining. Without ET-1 stimulation, phospho-HDAC2 was expressed in both nuclei and cytosol; meanwhile, HDAC2 and Sin3A were expressed mainly in nuclei (Fig. 3B). With ET-1 stimulation, the level of phospho-HDAC2 was increased in both nuclei and cytosol compared with control (Fig. 3B). However, no difference was observed in the level of HDAC2 and Sin3A (Fig. 3B).




Fig. 1 HDAC2 negatively regulated ET-1-induced CTGF production in WI-38 cells. **A** Cells were transfected with either 0.5 or 1 μg of HDAC2-HA plasmid or pcDNA for 24 h and were then treated with ET-1 for 2 h. The CTGF protein level was analyzed by Western blotting. Antibody specific for α-tubulin was applied to determine loading control. HA-tag was used to confirm the overexpression of HDAC2. Bars indicate the mean ± standard error of the mean (SEM; *n* = 4). **p* < 0.05 versus the group with ET-1 stimulation. **B** Cells were transfected with HDAC2 siRNA for 24 h and treated with ET-1 for 2 h; subsequently, the CTGF protein level was analyzed. Bars indicate the mean ± SEM (*n* = 5). #*p* < 0.05 versus control, **p* < 0.05 versus ET-1 treatment

Previous studies suggested that HDAC2 can be phosphorylated by JNK [39] and possibly by other members of the mitogen-activated protein kinase (MAPK) family, such as extracellular signal-regulated kinase (ERK) and p38 [44]. In this study, we investigated whether MAPKs mediate ET-1-induced HDAC2 phosphorylation and subsequent H3 acetylation. We found that pretreatment of cells with SP600125 (JNK inhibitor), U0126 (ERK inhibitor), or SB203580 (p38 inhibitor) attenuated ET-1-induced HDAC2 phosphorylation by 77% ± 25%, 89% ± 21%, and 96% ± 13% (*n* = 4; Fig. 3C) and mitigated ET-1-induced reduction in HDAC2 activity by 59% ± 17%, 62% ± 14%, and 69% ± 13%, respectively (*n* = 4; Fig. 3D). Furthermore, pretreatment of cells with SP600125, U0126, or SB203580 attenuated ET-1-induced H3 acetylation by 78% ± 14%, 92% ± 9%, and 111% ± 7%, respectively (*n* = 5; Fig. 3E). Thus, the ET-1-induced reduction in HDAC2 activity and increase in H3 acetylation were mediated by the JNK, ERK, and p38 pathways.

Sin3A and MeCP2 were negative regulators in ET-1-induced CTGF expression

MeCP2 recruits HDAC1, HDAC2, and Sin3A to promote the deacetylation of histone tails, thus resulting in gene silencing [28, 31]. In this study, we examined the role of Sin3A and MeCP2 in ET-1-induced CTGF production. Our results revealed that Sin3A overexpression (0.5 and 1 μg) attenuated ET-1-stimulated CTGF production in a dose-dependent manner (*n* = 4; Fig. 4A). Transfection of Sin3A siRNA (50 nM) into WI-38 cells enhanced ET-1-stimulated CTGF production by 148% ± 10% (*n* = 3; Fig. 4B). Further, overexpression of MeCP2 attenuated ET-1-stimulated CTGF expression in a dose-dependent manner (*n* = 6; Fig. 4C). Transfection of MeCP2 siRNA (50 nM) enhanced ET-1-stimulated CTGF expression by 192% ± 39% (*n* = 4; Fig. 4D). Thus, Sin3A and MeCP2 negatively regulated ET-1-stimulated CTGF production in WI-38 cells.

HDAC2 participated in the regulation of Sin3A- or MeCP2-suppressed H3 acetylation on CTGF promoter in ET-1-stimulated WI-38 cells

In order to evaluate the role of Sin3A and MeCP2 in the regulation of H3 acetylation on the CTGF promoter region, the ChIP assay was conducted. Overexpression of Sin3A or MeCP2 both suppressed ET-1-induced H3 acetylation on CTGF promoter region (*n* = 3; Fig. 5A). In addition, we investigated if suppression of ET-1-stimulated H3 acetylation by overexpression of Sin3A or




Fig. 2 ET-1 induced a decrease in HDAC2 activity and acetylation of H3. **A** Cells were stimulated with ET-1 for 5, 10, or 30 min. The cell lysates were immunoprecipitated with antibody specific for HDAC2, and then HDAC activity was detected. Bars indicate values of the mean \pm SEM ($n=3$). * $p < 0.05$ versus control group. **B** Cells were stimulated with ET-1 for 5, 10, 20, 30, or 60 min, and then the acetylation of histone H3 was evaluated using Western blotting. H3 was used as a loading control. Bars indicate mean \pm SEM ($n=4$). * $p < 0.05$ versus control group. **C** Cells were transfected with either 0.5 or 1 μ g of HDAC2-HA plasmid for 24 h and then treated with ET-1 for 20 min. Cells were subsequently lysed and immunoblotted with antibodies specific for histone H3, acetyl-H3, or HA. Bars indicate values of the mean \pm SEM ($n=4$). * $p < 0.05$ versus ET-1-treated group. **D** Cells were transfected with 1 μ g of HDAC7-GFP plasmid for 24 h and then treated with ET-1 for 20 min. Cells were subsequently lysed and immunoblotted with antibodies specific for histone H3, acetyl-H3, or GFP. Bars indicate values of the mean \pm SEM ($n=5$)

MeCP2 was dependent on the presence of HDAC2. We found that overexpression of Sin3A attenuated ET-1-stimulated H3 acetylation by $105\% \pm 6\%$, and this response was significantly recovered by transfection of HDAC2 siRNA ($n=5$; Fig. 5B). Moreover, MeCP2 overexpression reduced ET-1-stimulated H3 acetylation by $95\% \pm 6\%$, which this response was significantly reversed by transfection of HDAC2 siRNA ($n=5$; Fig. 5C). Thus, Sin3A- or MeCP2-suppressed ET-1-induced H3 acetylation on CTGF promoter region was dependent on the presence of HDAC2 in WI-38 cells.

ET-1 caused the disruption of HDAC2, Sin3A, and MeCP2 corepressor complexes and their subsequent dissociation from CTGF promoter

HDAC2 phosphorylation disrupts protein–protein interactions among corepressors HDAC2, Sin3A, and Yin Yang 1 [18]. Co-IP and ChIP assays were performed on ET-1-treated WI-38 cells to evaluate whether ET-1 disrupts the HDAC2/Sin3A/MeCP2 corepressor complex. The Co-IP assay indicated that ET-1 reduced protein–protein interactions among HDAC2, Sin3A, and MeCP2 (Fig. 6A–C). The ChIP assays revealed that ET-1 induced the dissociation of HDAC2, Sin3A, and MeCP2 from the CTGF promoter (Fig. 6D). Thus, ET-1 induced the disruption of the HDAC2/Sin3A/MeCP2 corepressor complex, which was followed by the dissociation of the complex from the CTGF promoter.

HDAC2 was involved in the regulation of Sin3A- or MeCP2-suppressed AP-1 transcriptional activity in ET-1-treated WI-38 cells

In our previous study, we revealed that ET-1 stimulated the production of CTGF through the ET_AR/JNK/




Fig. 3 JNK, ERK, and p38 were involved in ET-1-induced H3 acetylation through the regulation of HDAC2 phosphorylation and HDAC2 activity. **A** Cells were stimulated with ET-1 for 1, 3, 5, or 10 min and then lysed and immunoblotted with antibodies specific for HDAC2 or phospho-HDAC2 (S394). Bars indicate values of the mean \pm SEM ($n=3$). $*p < 0.05$ versus control group. **B** After ET-1 stimulation for 10 min, WI-38 cells were immunodetected with antibodies specific for phosphor-HDAC2 (purple), HDAC2 (green), and Sin3A (red); nuclei were detected with DAPI (blue). The nuclei is labeled by a white arrow. The cytosol is labeled by a white arrowhead. Bar, 50 μ m. **C** Cells were pretreated with 10 μ M of SP600125, U0126, or SB203580 or an equivalent vehicle control (dimethyl sulfoxide [DMSO]) for 30 min and then treated with ET-1 for 3 min. The cells were then lysed and immunoblotted with antibodies specific for HDAC2 or phospho-HDAC2 (S394). Bars indicate values of the mean \pm SEM ($n=4$). $*p < 0.05$ versus ET-1 stimulation. **D** Cells were pretreated with 10 μ M SP600125, 10 μ M U0126, or 10 μ M SB203580 or DMSO for 30 min and then stimulated with ET-1 for 20 min. The cell lysates were immunoprecipitated with antibodies specific for HDAC2, and then HDAC activity was detected. Bars indicate values of the mean \pm SEM ($n=4$). $*p < 0.05$, versus ET-1 stimulation. **E** Cells were pretreated with 10 μ M of SP600125, U0126, or SB203580 or DMSO for 30 min and then treated with ET-1 for 20 min. The cells were then lysed and immunoblotted with antibodies specific for histone H3 or acetyl-H3. Bars indicate values of the mean \pm SEM ($n=5$). $*p < 0.05$ versus ET-1 stimulation




Fig. 4 Sin3A and MeCP2 negatively regulated ET-1-induced CTGF production. **A** Cells were transfected with either 0.5 or 1 μg of Sin3A-HA plasmid or pcDNA for 24 h and then treated with ET-1 for 2 h. The protein levels of CTGF and HA-tag were evaluated through Western blotting. Bars indicate values of the mean ± SEM (*n* = 4). **p* < 0.05 versus the ET-1-treated group. **B** Sin3A was knocked down through transfection with siRNA for 24 h. After 2 h of stimulation with ET-1, the CTGF protein level was evaluated using Western blotting. Bars indicate values of the mean ± SEM (*n* = 3). **p* < 0.05 versus the ET-1 stimulation group. **C** Cells were transfected with either 0.5 or 1 μg of MeCP2-HA plasmid or pcDNA for 24 h and then treated with ET-1 for 2 h. The protein levels of CTGF and HA-tag were evaluated using Western blotting. Bars indicate values of the mean ± SEM (*n* = 6). **p* < 0.05 versus the ET-1 stimulation group. **D** MeCP2 was knocked down through transfection with siRNA for 24 h. After 2 h of stimulation with ET-1, the CTGF protein level was examined using Western blotting. Bars indicate values of the mean ± SEM (*n* = 4). **p* < 0.05 versus the ET-1-treated group

AP-1 signaling pathway [53]; ET-1 stimulation resulted in the recruitment of AP-1 to the CTGF promoter region and increased AP-1 transcriptional activity in WI-38 cells [53]. To elucidate the roles of HDAC2, Sin3A, and MeCP2 in regulating the transcriptional activity of AP-1, we examined the effect of HDAC2, Sin3A, or MeCP2 overexpression on ET-1-induced AP-1-luciferase activity. Transfection of HDAC2-HA

plasmid (1 μg) into WI-38 cells attenuated ET-1-induced AP-1-luciferase activity by 100% ± 26% (*n* = 5; Fig. 7A). Transfection of Sin3A-HA plasmid (0.5 μg) attenuated ET-1-induced AP-1-luciferase activity by 75% ± 6% (*n* = 5; Fig. 7B). Furthermore, transfection of HDAC2 siRNA significantly reversed Sin3A-suppressed ET-1-induced AP-1-luciferase activity (*n* = 5; Fig. 7B). Transfection of MeCP2-HA plasmid (0.5 μg)




Fig. 5 HDAC2 participated in the regulation of Sin3A- or MeCP2-suppressed H3 acetylation on CTGF promoter in ET-1-stimulated WI-38 cells. **A** Schematic of the 550-bp ChIP primer located on the CTGF promoter. Cells were transfected with either Sin3A-HA (1 µg) or MeCP2-HA plasmid (1 µg) for 24 h and then stimulated with ET-1 for 20 min, which was followed by ChIP assay. Nonimmune IgG was used as a negative control. Equal amounts of the soluble cross-linked chromatin present in each PCR were checked by the input ($n=3$). **B** Cells were transfected with Sin3A-HA plasmid (0.5 µg) or co-transfected with Sin3A-HA plasmid (0.5 µg) and HDAC2 siRNA (100 nM) for 24 h and then treated with ET-1 for 20 min. Cells were then lysed and immunoblotted with antibodies specific for histone H3, acetyl-H3, HDAC2, or HA. Bars indicate values of the mean \pm SEM ($n=5$). * $p < 0.05$ versus ET-1-treated cells, # $p < 0.05$ versus Sin3A-transfected cells with ET-1 stimulation. **C** Cells were transfected with MeCP2-HA plasmid (0.5 µg) or co-transfected with MeCP2-HA plasmid (0.5 µg) and HDAC2 siRNA (100 nM) for 24 h and then treated with ET-1 for 20 min. Cells were subsequently lysed and immunoblotted with antibodies specific for histone H3, acetyl-H3, HDAC2, or HA. Bars indicate values of the mean \pm SEM ($n=5$). * $p < 0.05$ versus ET-1-treated cells, # $p < 0.05$ versus MeCP2-transfected cells with ET-1 stimulation

suppressed ET-1-induced AP-1-luciferase activity by $79\% \pm 2\%$ ($n=4$; Fig. 7C). Furthermore, MeCP2-suppressed ET-1-induced AP-1-luciferase activity was significantly recovered by transfection of HDAC2 siRNA ($n=4$; Fig. 7C). Thus, Sin3A- or MeCP2-regulated suppression of ET-1-stimulated AP-1 transcriptional activity was dependent on the presence of HDAC2 in WI-38 cells.

H3 acetylation was correlated with HDAC2 and Sin3A expression, but not MeCP2, in OVA-induced airway fibrosis
 In a previous study, we demonstrated that the expressions of CTGF and fibrotic proteins, such as α -SMA and collagen, were increased in the lungs in an OVA-induced airway fibrosis model [10]. In this study, we evaluated the roles of HDAC2, Sin3A, and MeCP2 in OVA-induced airway fibrosis. The HDAC2, Sin3A, and MeCP2 protein levels, as well as HDAC2 phosphorylation and H3 acetylation, were analyzed using Western blotting. We observed that the ratio of phospho-HDAC2/HDAC2 was increased in the lung tissue of OVA-treated mice compared with the control group ($n=10$; Fig. 8A, B). HDAC2 and Sin3A expression was lower ($n=10$; Fig. 8A, C, D) in the lung tissue of OVA-treated mice compared with the control group. However, no significant difference was noted in the expression of MeCP2 ($n=10$; Fig. 8A, E). H3 acetylation was markedly higher ($n=10$; Fig. 8A, F) in the lung tissue of OVA-stimulated mice compared with the




Fig. 6 ET-1 treatment disrupted protein–protein interactions among HDAC2, Sin3A, and MeCP2 and induced dissociation of these corepressors from CTGF promoter region. Cells were stimulated with ET-1 for 20 min followed by the collection of lysates. Immunoprecipitation was then conducted with **A** HDAC2 ($n=5$), **B** Sin3A ($n=5$), or **C** MeCP2 ($n=4$) antibodies. The protein–protein interaction among HDAC2, Sin3A, and MeCP2 was determined through Western blotting. **D** Schematic of the 550-bp ChIP primer located on the CTGF promoter. Cells were stimulated with ET-1 for 20 min, which was followed by ChIP assay. Nonimmune IgG was used as a negative control. Equal amounts of the soluble cross-linked chromatin present in each PCR were checked by the input ($n=5$)

control group. Furthermore, using IF staining, the phosphorylation of HDAC2, and the expression of HDAC2 and Sin3A in the lung sections from the OVA-treated mice were examined. We found that the level of phospho-HDAC2, HDAC2, and Sin3A were reduced in the airway wall of OVA-treated mice compared with PBS-treated mice (Fig. 8G). Thus, an increase in H3 acetylation and a reduction in the protein levels in HDAC2 and Sin3A, but not MeCP2, might contribute to the pathogenesis of airway fibrosis.




Fig. 7 HDAC2 was involved in the regulation of Sin3A- or MeCP2-suppressed AP-1 transcriptional activity in ET-1-treated WI-38 cells. **A** Cells were transfected with HDAC2-HA (1 µg), AP-1-luciferase plasmid (1 µg), or pBK-CMV-Lac Z (0.1 µg) for 24 h and then stimulated with ET-1 for 16 h. Bars indicate values of mean \pm SEM ($n=5$). * $p < 0.05$ versus ET-1 stimulation. **B** Cells were transfected with AP-1-luciferase plasmid (1 µg) and pBK-CMV-Lac Z (0.1 µg) and then transfected with Sin3A-HA (0.5 µg) or co-transfected with Sin3A-HA (0.5 µg) and HDAC2 siRNA (100 nM) for 24 h. Cells were stimulated with ET-1 for 16 h. Luciferase activity was evaluated as described in “Materials and methods”. Bars indicate values of mean \pm SEM ($n=5$). * $p < 0.05$ versus ET-1-treated cells, # $p < 0.05$ versus Sin3A-transfected cells with ET-1 stimulation. **C** Cells were transfected with AP-1-luciferase plasmid (1 µg) and pBK-CMV-Lac Z (0.1 µg) and then transfected with MeCP2-HA (0.5 µg) and HDAC2 siRNA (100 nM) for 24 h. Cells were stimulated with ET-1 for 16 h. Luciferase activity was evaluated as described in “Materials and methods”. Bars indicate values of mean \pm SEM ($n=5$). * $p < 0.05$ versus ET-1-treated cells, # $p < 0.05$ versus MeCP2-transfected cells with ET-1 stimulation

Discussion

ET-1 plays a vital role in lung fibrosis. The plasma concentration of ET-1 was reported to increase in patients with idiopathic pulmonary fibrosis [51]. ET-1 promotes fibroblast activation and differentiation, which lead to excessive ECM deposition [47]. Our previous study indicated that ET-1 stimulates the expression of CTGF through the ET_AR/JNK/AP-1 signaling pathway and that CTGF is required for ET-1-stimulated myofibroblast differentiation [53]. Moreover, ET-1 activates p300 and HDAC7 to initiate AP-1 transcriptional activity and eventually promotes the expression of CTGF [22]. In this study, we found that ET-1 increased HDAC2 phosphorylation through MAPKs and then induced the dissociation of the HDAC2/Sin3A/MeCP2 corepressor complex from the CTGF promoter region, which in turn promoted histone H3 acetylation, thus increasing CTGF expression.

Histone acetylation results in the opening up of the chromatin structure, thereby allowing the binding of RNA polymerase II and transcriptions [23]. One study reported that histone acetylation might directly mediate inflammatory cytokine expression and that it participates in the progression of lung fibrosis [36]. Histone H3 acetylation was reported to contribute to the overexpression of profibrotic cytokine interleukin-6 in paraquat-induced pulmonary fibrosis [21]. HDAC2-containing complexes are critical regulators of histone acetylation [29]. In this study, HDAC2 overexpression inhibited ET-1-induced CTGF production and H3 acetylation in human lung fibroblasts. Transfection with HDAC2 siRNA enhanced ET-1-stimulated CTGF production. ET-1 stimulation reduced HDAC2 activity and increased H3 acetylation. Thus, HDAC2 negatively regulates CTGF expression through the suppression of H3 acetylation. Following ET-1 stimulation, the reduction of HDAC2 activity prompts an increase in H3 acetylation, which in turn promotes CTGF expression. On the other hand, our previous study found that activation of HDAC7 was involved in ET-1-stimulated CTGF expression in human lung fibroblasts [22]. In this study, we found that overexpression of HDAC7 did not affect ET-1-stimulated H3 acetylation in WI-38 cells. Thus, ET-1-stimulated H3 acetylation was not regulated by HDAC7.

In one study, HDAC2 phosphorylation at serine sites S394, S422, and S424 negatively regulated its deacetylase activity; further, cigarette smoke attenuated the deacetylase activity of HDAC2 through casein kinase

2-mediated phosphorylation of HDAC2 [1]. Additionally, HDAC2 can possibly be phosphorylated by members of the MAPK family [44]. In this study, we demonstrated the following: ET-1 induces the increase in HDAC2 phosphorylation (S394), which was elevated in both nuclei and cytosol; pretreatment with JNK, ERK, or p38 inhibitors attenuates ET-1-induced HDAC2 phosphorylation and histone H3 acetylation; and the ET-1-induced reduction in HDAC2 activity is mitigated by JNK, ERK, or p38 inhibitors. Thus, ET-1 mediates the decrease in HDAC2 activity through MAPKs-mediated HDAC2 phosphorylation at S394. Indeed, as previous study suggested that S394 is responsible for the cardiac hypertrophy-associated activation of HDAC2 [17]. HDAC2 phosphorylation at S394 is important for the regulation of HDAC2 activity and its interactions with mSin3 and Mi2 [49]. On the other hand, a previous study suggested that all-trans retinoic acid-induced HDAC2 phosphorylation at S424 is mediated by JNK signaling [39]. However, the role of MAPKs in regulation of ET-1-stimulated HDAC2 phosphorylation at S422 and S424 still needs further study. In this study, we found that inhibitors of JNK, ERK, and p38 suppressed ET-1-stimulated HDAC2 phosphorylation at S394 by 77%, 89% and 96%, respectively. The p38 inhibitor possessed the highest level of inhibition rate. As a result, p38 may be the most important regulator in HDAC2 phosphorylation at S394.

HDAC2 is a prominent corepressor complex. These complexes also contain other specific proteins, such as Sin3A, crucial for HDAC2's binding to DNA, recruitment to specific promoter sequences, and modulation of deacetylase activity [20]. A previous study suggested that loss of Sin3A drives alveolar type 2 cell dysfunction and progressive lung fibrosis in mice [57]. In addition, MeCP2 recruits HDAC2 and Sin3A to promote the deacetylation of histone tails, which results in gene silencing [28]. In this study, transfection of Sin3A or MeCP2 siRNA enhanced ET-1-stimulated CTGF production. Overexpression of Sin3A or MeCP2 attenuated ET-1-stimulated CTGF production. ET-1-induced H3 acetylation on CTGF promoter region was attenuated by overexpression of Sin3A or MeCP2. Sin3A- or MeCP2-suppressed ET-1-induced H3 acetylation were reversed by transfection with HDAC2 siRNA. These results suggest that HDAC2 is involved in the regulation of Sin3A- and MeCP2-suppressed H3 acetylation on CTGF promoter region, which results in inhibition of CTGF production

(See figure on next page.)

Fig. 8 The level of phospho-HDAC2, HDAC2, Sin3A, and MeCP2 and acetylation of H3 in the lungs of mice with OVA-induced airway fibrosis. **A** The level of phospho-HDAC2, HDAC2, Sin3A, MeCP2, and acetylation of H3 in the lungs from PBS-treated or OVA-treated mice were evaluated through Western blotting. **B–F** Statistical analysis of protein levels. Horizontal lines indicate mean values, and each dot represents an individual mouse ($n = 10$). * $p < 0.05$ versus PBS group. **G** Paraffin sections of lung tissue from the PBS- or OVA-treated mice were stained for phospho-HDAC2 (purple), HDAC2 (green), Sin3A (red), and nuclei (blue). Bar, 50 μ m





Fig. 8 (See legend on previous page.)



◀ **Fig. 9** Schematic of how ET-1 signal transduction promotes CTGF production. **A** Without stimulation, HDAC2 inhibits CTGF production through the formation of a corepressor complex with Sin3A and MeCP2, thereby suppressing H3 acetylation on the CTGF promoter. **B** With ET-1 stimulation, MAPKs mediate HDAC2 phosphorylation, which is followed by the disruption of the corepressor complex and acetylation of H3 in the CTGF promoter region; this prompts the opening up of the chromatin structure to allow binding of AP-1. By contrast, ET-1 recruits AP-1 to the CTGF promoter region through JNK-mediated AP-1 phosphorylation and HDAC7/p300/AP-1 transcriptional complex formation, which in turn induces CTGF expression

ET-1-caused AP-1-luciferase activity. Moreover, Sin3A- or MeCP2-suppressed ET-1-stimulated AP-1-luciferase activity were reversed by transfection with HDAC2 siRNA. Thus, without stimulation, HDAC2 forms a corepressor complex with Sin3A and MeCP2 to inhibit H3 acetylation and AP-1 binding of CTGF promoter, thereby suppressing CTGF expression. Following ET-1 stimulation, the HDAC2/Sin3A/MeCP2 corepressor complex dissociates from the CTGF promoter region; subsequently, the increase in H3 acetylation allowing the binding of AP-1 to the CTGF promoter region, which results in an increase in AP-1 activity and stimulation of CTGF expression.

Airway remodeling is characterized by subepithelial fibrosis [4] and contributes to the progressive loss of lung function in asthma [41]. A previous study suggested that the presence of ET-1 is necessary to activate bronchial fibroblast proliferation and collagen synthesis in patients with asthma [16]. Moreover, ET-1 directs airway remodeling and hyper-reactivity in a murine asthma model [19]. In addition, ET-1 is increased in the bronchoalveolar lavage fluid from OVA-challenged mice and is involved in the process of subepithelial fibrosis [7]. In our previous studies, the expressions of CTGF, α -SMA, and collagen were increased in the lungs in an OVA-induced airway fibrosis model [10], and the HDAC7 overexpression might play an important role in the pathogenesis of OVA-induced airway fibrosis [22]. A related study suggested that an increase in H3 acetylation in lung tissue was associated with asthma pathogenesis [45]. In this study, we also found that histone H3 acetylation considerably increased in lung tissue of OVA-stimulated mice. Thus, the increase in H3 acetylation might be involved in the pathogenesis of OVA-induced airway fibrosis. HDAC2-containing complexes are vital mediators of histone deacetylation in vivo [29]. In another study, HDAC2 formed a corepressor complex with MeCP2 and Sin3A to promote the deacetylation of histone tails, which resulted in gene silencing [28]. In inflammatory lung diseases, such

in ET-1-treated cells. Furthermore, ET-1 induced the disruption of the HDAC2/Sin3A/MeCP2 corepressor complex and prompted the corepressor complex's dissociation from the CTGF promoter region. Our previous study revealed that AP-1 participates in ET-1-stimulated CTGF expression [22]. In this study, we also found that overexpression of HDAC2, Sin3A, or MeCP2 attenuated

as COPD and severe asthma, a reduction in the HDAC2 protein level or HDAC2 activity is commonly observed [2]. One study reported that HDAC2 activation could prevent airway remodeling through the suppression of airway inflammation and the modulation of fibroblast activation in COPD [33]. In the present study, HDAC2 phosphorylation and protein level of HDAC2 and Sin3A significantly decreased in the lung of OVA-stimulated mice. Although the level of phospho-HDAC2 and HDAC2 were both decreased, the ratio of phospho-HDAC2/HDAC2 was significantly increased in the lung of OVA-stimulated mice. Moreover, IF staining also showed that the level of HDAC2 and Sin3A were reduced in the airway wall of OVA-treated mice compared with control group. These results suggest that HDAC2 phosphorylation and the loss of HDAC2 and Sin3A levels might be involved in the pathogenesis of OVA-caused airway fibrosis. On the other hand, MeCP2 is instrumental to the deacetylation activity of HDACs. MeCP2 recruits HDACs and Sin3 to methylated DNA and suppresses gene expression [27]. However, we observed that the MeCP2 protein level was unchanged in the lung tissue of an OVA-induced airway fibrosis model. Therefore, MeCP2 protein level may play less of a role than HDAC2 and Sin3A in the pathogenesis of OVA-induced airway fibrosis.

Conclusions

Without stimulation, the HDAC2/Sin3A/MeCP2 corepressor complex inhibited CTGF expression through H3 deacetylation in the CTGF promoter region (Fig. 9A). HDAC2, Sin3A, and MeCP2 served as the corepressors of CTGF expression. With ET-1 stimulation, HDAC2 activity was reduced through MAPK-mediated HDAC2 phosphorylation followed by dissociation of the HDAC2 corepressor complex from the CTGF promoter as well as H3 acetylation; subsequently, the chromatin structure opened up to allow binding of AP-1, which in turn caused CTGF production (Fig. 9B). The present results, together with those of our previous reports, suggest the following: ET-1 stimulation induces AP-1 activation through the ET_AR/JNK pathway [53] as well as the formation of the HDAC7/p300/AP-1 transcriptional complex [22]; subsequently, transcriptional complex is recruited to the CTGF promoter, thereby stimulating CTGF production (Fig. 9B). Our results highlight the vital role of the HDAC2/Sin3A/MeCP2 corepressor complex in preventing CTGF production in human lung fibroblasts. Further, pathologic loss of HDAC2 and Sin3A rather than MeCP2 may be a key determinant in the pathogenesis of airway fibrosis.

Abbreviations

AP-1	Activator protein-1
ChIP	Chromatin immunoprecipitation
COPD	Chronic obstructive pulmonary disease
CTGF	Connective tissue growth factor
ECM	Extracellular matrix
ERK	Extracellular signal-regulated kinase
ET	Endothelin
ET _A R	ETA receptor
FBS	Fetal bovine serum
HDAC	Histone deacetylase
IF	Immunofluorescence
JNK	C-Jun N-terminal kinases
MAPK	Mitogen-activated protein kinase
MECP	Methyl-CpG-binding protein
MEM	Minimum essential medium
OVA	Ovalbumin
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
siRNA	Small interfering RNA
TGF-β	Transforming growth factor-β

Acknowledgements

This study was supported by the Ministry of Science and Technology of Taiwan (MOST-104-2320-B-038-002-MY3). The authors have no conflicts of interest to declare.

Author contributions

HSH, HCW, CMW, HPK, BCC, and CHL conceived and designed the experiments. HSH, HCW, CMW, HSL, and FSU performed the experiments. HSH, HPK, BCC, and CHL analyzed the data. HSH wrote the paper. All authors read and approved the final manuscript.

Funding

This study was supported by the National Science and Technology Council (MOST-104-2320-B-038-002-MY3).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All animal experimental protocols were approved by Taipei Medical University Institutional Animal Care and Use Committee (LAC-101-0243).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan. ²School of Respiratory Therapy, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan. ³Division of Thoracic Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. ⁴Research Center of Thoracic Medicine, Taipei Medical University, Taipei, Taiwan. ⁵Department of Thoracic Medicine, Taipei Medical University Hospital, Taipei, Taiwan. ⁶Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Received: 23 November 2022 Accepted: 20 May 2023
Published online: 14 June 2023

References

- Adenuga D, Rahman I. Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2 by cigarette smoke and aldehydes. *Arch Biochem Biophys*. 2010;498(1):62–73.
- Barnes PJ. Histone deacetylase-2 and airway disease. *Ther Adv Respir Dis*. 2009;3(5):235–43.
- Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. *Eur Respir J*. 2005;25(3):552–63.
- Bergeron C, Al-Ramli W, Hamid Q. Remodeling in asthma. *Proc Am Thorac Soc*. 2009;6(3):301–5.
- Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. *J Biol Chem*. 2001;276(48):45184–92.
- Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. *Ther Adv Respir Dis*. 2015;9(6):281–93.
- Cai C, Xu J, Zhang M, Chen XD, Li L, Wu J, Lai HW, Zhong NS. Prior SO₂ exposure promotes airway inflammation and subepithelial fibrosis following repeated ovalbumin challenge. *Clin Exp Allergy*. 2008;38(10):1680–7.
- Chen HP, Zhao YT, Zhao TC. Histone deacetylases and mechanisms of regulation of gene expression. *Crit Rev Oncog*. 2015;20(1–2):35–47.
- Chen HY, Lin CH, Chen BC. ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts. *Exp Cell Res*. 2018;370(1):39–45.
- Chen JY, Cheng WH, Lee KY, Kuo HP, Chung KF, Chen CL, Chen BC, Lin CH. Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma. *Biomed Pharmacother*. 2021;140: 111701.
- Chen JY, Lin CH, Chen BC. Hypoxia-induced ADAM 17 expression is mediated by RSK1-dependent C/EBPbeta activation in human lung fibroblasts. *Mol Immunol*. 2017;88:155–63.
- Chen L, Charrier A, Zhou Y, Chen R, Yu B, Agarwal K, Tsukamoto H, Lee LJ, Paulaitis ME, Brigstock DR. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. *Hepatology*. 2014;59(3):1118–29.
- Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. *Am J Respir Crit Care Med*. 2004;170(2):141–7.
- Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ, Pang L. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. *FASEB J*. 2014;28(7):3183–96.
- Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. *Int Rev Cytol*. 2007;257:143–79.
- Dube J, Chakir J, Dube C, Grimard Y, Laviolette M, Boulet LP. Synergistic action of endothelin (ET)-1 on the activation of bronchial fibroblast isolated from normal and asthmatic subjects. *Int J Exp Pathol*. 2000;81(6):429–37.
- Eom GH, Cho YK, Ko JH, Shin S, Choe N, Kim Y, Joung H, Kim HS, Nam KI, Kee HJ, Kook H. Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. *Circulation*. 2011;123(21):2392–403.
- Galasinski SC, Resing KA, Goodrich JA, Ahn NG. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. *J Biol Chem*. 2002;277(22):19618–26.
- Gregory LG, Jones CP, Mathie SA, Pegorier S, Lloyd CM. Endothelin-1 directs airway remodeling and hyper-reactivity in a murine asthma model. *Allergy*. 2013;68(12):1579–88.
- Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. *Cell*. 1997;89(3):341–7.
- Hu L, Yu Y, Huang H, Fan H, Hu L, Yin C, Li K, Fulton DJ, Chen F. Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis. *Front Immunol*. 2016;7:696.
- Hua HS, Wen HC, Weng CM, Lee HS, Chen BC, Lin CH. Histone deacetylase 7 mediates endothelin-1-induced connective tissue growth factor expression in human lung fibroblasts through p300 and activator protein-1 activation. *J Biomed Sci*. 2021;28(1):38.
- Ito K, Charron CE, Adcock IM. Impact of protein acetylation in inflammatory lung diseases. *Pharmacol Ther*. 2007;116(2):249–65.
- Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med*. 2005;352(19):1967–76.
- Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. *J Exp Med*. 2006;203(1):7–13.
- John SP, Sun J, Carlson RJ, Cao B, Bradfield CJ, Song J, Smelkinson M, Fraser IDC. IFIT1 exerts opposing regulatory effects on the inflammatory and interferon gene programs in LPS-activated human macrophages. *Cell Rep*. 2018;25(1):95–106.e106.
- Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. *Nat Genet*. 1998;19(2):187–91.
- Kavalali ET, Nelson ED, Monteggia LM. Role of MeCP2, DNA methylation, and HDACs in regulating synapse function. *J Neurodev Disord*. 2011;3(3):250–6.
- Kelly RDW, Chandru A, Watson PJ, Song Y, Blades M, Robertson NS, Jamieson AG, Schwabe JWR, Cowley SM. Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo. *Sci Rep*. 2018;8(1):14690.
- Khan DH, He S, Yu J, Winter S, Cao W, Seiser C, Davie JR. Protein kinase CK2 regulates the dimerization of histone deacetylase 1 (HDAC1) and HDAC2 during mitosis. *J Biol Chem*. 2013;288(23):16518–28.
- Kishi N, Macklis JD. Dissecting MECP2 function in the central nervous system. *J Child Neurol*. 2005;20(9):753–9.
- Kobayashi Y, Bossley C, Gupta A, Akashi K, Tsartsali L, Mercado N, Barnes PJ, Bush A, Ito K. Passive smoking impairs histone deacetylase-2 in children with severe asthma. *Chest*. 2014;145(2):305–12.
- Lai T, Tian B, Cao C, Hu Y, Zhou J, Wang Y, Wu Y, Li Z, Xu X, Zhang M, Xu F, Cao Y, Chen M, Wu D, Wu B, Dong C, Li W, Ying S, Chen Z, Shen H. HDAC2 suppresses IL17A-mediated airway remodeling in human and experimental modeling of COPD. *Chest*. 2018;153(4):863–75.
- Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potential clinical bio-marker of fibroproliferative disease? *J Cell Commun Signal*. 2009;3(2):89–94.
- Li LB, Leung DY, Martin RJ, Goleva E. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma. *Am J Respir Crit Care Med*. 2010;182(7):877–83.
- Li M, Zheng Y, Yuan H, Liu Y, Wen X. Effects of dynamic changes in histone acetylation and deacetylase activity on pulmonary fibrosis. *Int Immunopharmacol*. 2017;52:272–80.
- Lin CH, Shih CH, Lin YC, Yang YL, Chen BC. MEK1, JNK, and SMAD3 mediate CXCL12-stimulated connective tissue growth factor expression in human lung fibroblasts. *J Biomed Sci*. 2018;25(1):19.
- Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. *Fibrogenesis Tissue Repair*. 2012;5(Suppl 1):S24.
- Meng F, Han M, Zheng B, Wang C, Zhang R, Zhang XH, Wen JK. All-trans retinoic acid increases KLF4 acetylation by inducing HDAC2 phosphorylation and its dissociation from KLF4 in vascular smooth muscle cells. *Biochem Biophys Res Commun*. 2009;387(1):13–8.
- Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, Steadman R. Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 colocalization in lipid rafts. *J Biol Chem*. 2013;288(21):14824–38.
- Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. *J Allergy Clin Immunol*. 2005;116(3):477–86 (quiz 487).
- Pegorier S, Arouche N, Dombret MC, Aubier M, Pretolani M. Augmented epithelial endothelin-1 expression in refractory asthma. *J Allergy Clin Immunol*. 2007;120(6):1301–7.
- Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. *Arthritis Rheum*. 2009;60(7):2142–55.

44. Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. *Antioxid Redox Signal*. 2008;10(4):799–811.
45. Ren Y, Li M, Bai S, Kong L, Su X. Identification of histone acetylation in a murine model of allergic asthma by proteomic analysis. *Exp Biol Med (Maywood)*. 2021;246(8):929–39.
46. Saunders A, Huang X, Fidalgo M, Reimer MH Jr, Faiola F, Ding J, Sanchez-Priego C, Guallar D, Saenz C, Li D, Wang J. The SIN3A/HDAC corepressor complex functionally cooperates with NANOG to promote pluripotency. *Cell Rep*. 2017;18(7):1713–26.
47. Swigris JJ, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. *BioDrugs*. 2010;24(1):49–54.
48. Tsai CC, Wu SB, Kau HC, Wei YH. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-beta1 (TGF-beta1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts. *Sci Rep*. 2018;8(1):7276.
49. Tsai SC, Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. *J Biol Chem*. 2002;277(35):31826–33.
50. Turner AM, Tamasi L, Schleich F, Hoxha M, Horvath I, Louis R, Barnes N. Clinically relevant subgroups in COPD and asthma. *Eur Respir Rev*. 2015;24(136):283–98.
51. Ugucioni M, Pulsatelli L, Grigolo B, Facchini A, Fasano L, Cinti C, Fabbri M, Gasbarrini G, Meliconi R. Endothelin-1 in idiopathic pulmonary fibrosis. *J Clin Pathol*. 1995;48(4):330–4.
52. Weng CM, Chen BC, Wang CH, Feng PH, Lee MJ, Huang CD, Kuo HP, Lin CH. The endothelin A receptor mediates fibrocyte differentiation in chronic obstructive asthma. The involvement of connective tissue growth factor. *Am J Respir Crit Care Med*. 2013;188(3):298–308.
53. Weng CM, Yu CC, Kuo ML, Chen BC, Lin CH. Endothelin-1 induces connective tissue growth factor expression in human lung fibroblasts by ETAR-dependent JNK/AP-1 pathway. *Biochem Pharmacol*. 2014;88(3):402–11.
54. Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeke E, Verschakelen JA, Wells AU, Verleden GM. The pathogenesis of pulmonary fibrosis: a moving target. *Eur Respir J*. 2013;41(5):1207–18.
55. Wynn TA. Integrating mechanisms of pulmonary fibrosis. *J Exp Med*. 2011;208(7):1339–50.
56. Yang Z, Sun Z, Liu H, Ren Y, Shao D, Zhang W, Lin J, Wolfram J, Wang F, Nie S. Connective tissue growth factor stimulates the proliferation, migration and differentiation of lung fibroblasts during paraquat-induced pulmonary fibrosis. *Mol Med Rep*. 2015;12(1):1091–7.
57. Yao C, Guan X, Carraro G, Parimon T, Liu X, Huang G, Mulay A, Soukiasian HJ, David G, Weigt SS, Belperio JA, Chen P, Jiang D, Noble PW, Stripp BR. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. *Am J Respir Crit Care Med*. 2020;203(6):707–17.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

